Nineteen children and adolescents receiving repeated transfusions and subcutaneous desferrioxamine treatment were investigated in an attempt to quantitate iron overload non-invasively. Before patients were started on desferrioxamine individual relationships were correlated for 12 to 36 months between transfused iron, absorbed iron estimated gastrointestinally, and increasing serum ferritin concentrations. Patients with inflamma-
each individual patient. All patients showed close correlation (R2) between x and y (median R2 of0909, 098, and 0-92 in thalassaemia, aplastic anaemia, and sickle cell anaemia patients, respectively). When started on desferrioxamine, current serum ferritin concentrations were used to derive the iron overload from each individual regression curve. The derived estimated iron overload ranged from 0*6 g to 31 g. Left ventricular dilatation was observed in three patients with 1 thalassaemia and in one patient with aplastic anaemia with median iron overload of 20*7 (14.1-31-3) g and 24-0 g respectively. Hypothyroidism was found in four patients with 1 thalassaemia and one patient with aplastic anaemia with iron overload between 14-7 (6-8 and 26-1) g and 1541 g respectively. Human growth hormone deficiency was detected in three patients with 1 thalassaemia with an iron overload of 4-2 (3-5-6-8) g; all three patients had excellent desferrioxamine compliance.
Secondary haemochromatosis with cardiomyopathy, liver cirrhosis, hypogonadism, delayed puberty, and diabetes are the most common complications ofhigh transfusion regimens in children with 1 thalassaemia, aplastic anaemia, and other refractory anaemias.I After the introduction of chelation treatment with desferrioxamine, estimating iron overload became extremely important for therapeutic monitoring. One of the best and most reliable ways to estimate iron overload non-invasively is to determine the serum ferritin concentration, which correlates with rising parenchymal and non-parenchymal iron stores.2 3 One problem of this method is the wide range in the relationship between stored iron and ferritin (between 5 and 10 mg iron/ng ferritin/ml4). Other problems such as liver enzyme elevations, haemolysis, tumours, and inflammation may also influence this relationship.
In patients with severe haemochromatosis, other non-invasive techniques have been introduced such as SQUID (superconducting quantum interference device), dual energy computed tomography, and magnetic resonance imaging.5-7 All are expensive and time consuming and children require sedation or even anaesthesia. Other techniques, such as liver biopsy with measurement of liver iron content, are invasive with a risk of intraabdominal bleeding.8 9 The aim of this study was to improve the individual reliability of serum ferritin monitoring in patients with secondary iron overload using a simple logarithmic quantitation model that individualises the relationship of serum ferritin and iron stores.
Subjects and methods Nineteen patients with refractory anaemia (14 with 1 thalassaemia major, aged 3-18 years; four with aplastic anaemia, aged 16-18 years; and one with sickle cell anaemia, aged 5 years) were investigated between 1975 and 1992. All patients received regular leucocyte-poor red blood cell preparations every 2-4 weeks to maintain haemoglobin concentrations >100 g/l. Since 1979, subcutaneous desferrioxamine (5-7 times/week, 30-100 mg/kg body weight) was given in those with imminent iron overload (ferritin concentrations >1500 pug/l). A transfusion requirement exceeding 240 ml/kg/year was considered an indication for splenectomy (n=3). Measurements of urinary iron excretion (phpnanthroline and tripyridiltriazine method) were regularly done to determine the most effective desferrioxamine dosage (faecal iron excretion was estimated to be 50% of total iron excretion).10 Amounts of transfused blood were noted and summated in each patient (200 ml leucocyte-poor blood= 200 mg iron).
Serum ferritin concentrations were determined simultaneously and were excluded in 4Gingor, Rohrbach, Solem, Kaltwasser, Kornhuber patients with inflammation, increases in liver enzymes, or haemolysis.
As the majority of thalassaemic patients were on a high transfusion regimen (inhibiting erythropoeisis and excessive gastrointestinal iron absorption) from their first year of life their gastrointestinal iron absorption was estimated to be about 1 5% of food iron (table 1) .
In those thalassaemic patients, who first received transfusions after infancy or had chronically low haemoglobin concentrations of <80 g1l (no transfusions, after splenectomy) iron absorption was estimated to be about 30% of food iron (table 1). 11 The correlation between serum ferritin concentrations and iron overload is described as a logarithmic regression curve or exponential curve.4 First, we determined the relationship between serum ferritin and iron overload in individual patients before desferrioxamine treatment was started. For this purpose each patient had serial serum ferritin measurements made during a period of 12-36 months. The level of iron stores was taken as 'transfused iron' (1 mg iron/ml blood transfused). For this period of time, gastrointestinal iron absorption was ignored in those patients who received their first blood transfusion in the first 12 months of life (y=transfused iron=iron overload=a+b log [x=serum ferritin]). In others, who received their first blood transfusion after infancy, we estimated gastrointestinally absorbed iron and calculated iron stores as transfused iron plus absorbed iron (y=trans-fused iron [+ gastrointestinally resorbed iron] = iron overload=a+b log [x= serum ferritin]). We plotted serum ferritin concentrations against iron load, producing regression curves for each patient (figs 1 and 2).
After desferrioxamine had been started, we measured serum ferritin concentrations and, using the regression curves previously determined for individual patients, derived a value for iron overload after desferrioxamine for each child. Next, we subtracted from this value the total amount of iron transfused and absorbed through the gastrointestinal tract to give a value for total faecal and urinary excretion of iron (table 2) .
At the same time as measuring ferritin and iron overload, all patients had a regular (every [6] [7] [8] [9] [10] [11] [12] (table 3) . Human growth hormone deficiency was detected in three patients with 3 thalassaemia with a median iron overload of 4-2 (3 5-6 8) g; all three patients had excellent desferrioxamine compliance (table 3) . Discussion Non-invasive estimation of iron overload in secondary haemochromatosis is one of the main problems in monitoring desferrioxamine treatment. Although desferrioxamine is able to prevent and partially reverse tissue damage due to iron overload,12-15 to some degree, damage may be irreversible.
We have used a method to 'individualise' the relationship between iron overload and serum ferritin. The major part of iron load in chronic anaemia is the amount of transfused iron, which is easily calculated. Gastrointestinally absorbed iron can be a source of considerable iron loading in patients with ,B thalassaemia10 without regular transfusions. Consequently, in cases of a thalassaemia with longer periods of anaemia 680 g/l (for example, no transfusion due to splenectomy, 3 thalassaemia intermedia, or caused by poverty) an estimate of gastrointestinally absorbed iron must be added to the amount of transfused iron before forming the ferritin-iron overload regression curve. In patients with aplastic anaemia, sickle cell anaemia, and a thalassaemia who are on high transfusion regimens, gastrointestinal iron absorption can be ignored in forming the ferritin-iron overload regression curve.10 When exclusion criteria for ferritin are considered, the relationship between transfused iron (plus gastrointestinally absorbed iron), liver iron content, and ferritin is close.3 4 16 As myocardial siderosis is a significant contributing factor in the early death of patients with refractory anaemias13 17 we tried to confirm our iron studies by evaluating the cardiovascular status of our patients. According to our data, an iron overload of -14 g (ferritin about 4000-5000,ug/l) during desferrioxamine treatment can cause left ventricular dilatation due to cardiomyopathy (table 3) .
Other investigations showed early cardiomyopathy after transfusion with 100 units of blood (about 20 g iron) in patients without desferrioxamine.18 This discrepancy might be explained by the fact that those patients with cardiomyopathy had received a total amount of iron greater than 30 g which might have damaged cardiac tissue before being partially removed by intensive desferrioxamine treatment. The same threshold of 14 g iron overload was also observed in hypothyroidism. All patients with hypothyroidism had an iron overload of >s 14 g except for one with an estimated iron overload of about 7 g (total received iron 33 g, current serum ferritin 4000 ,ug/l). This child had unexplained high ferritin concentrations even though the estimated iron overload was quite low and the desferrioxamine compliance was good. This patient will need a liver biopsy.
We discovered that all children with abnormal growth hormone values had a low iron burden and excellent desferrioxamine compliance ( 
